Lateral Flow Immunoassay for Early Bordetella pertussis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing pertussis are inadequate due to non-specific symptoms and the lack of rapid, point-of-care assays that can detect Bordetella pertussis at the early stages of the disease, leading to delayed treatment and increased transmission.
Innovation Solution
Development of antibodies specific to tracheal colonization factor A (TcfA) for use in lateral flow immunoassays, allowing for early detection of Bordetella pertussis in nasopharyngeal samples, which can be administered to prevent or treat the infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bacterial culture is used for diagnosis, then early detection is possible, but the assay time is very slow (5-7 days) and cannot be performed at point of care
Solution Approach 1:
The patent replaces the slow bacterial culture method with a lateral flow immunoassay that uses antibody-antigen binding reactions instead of mechanical bacterial growth processes. This substitution enables rapid detection within minutes while maintaining diagnostic accuracy, resolving the contradiction between detection capability and assay time.
2Measurement precision
If PCR or DNA amplification assays are used, then detection sensitivity is improved, but the assays are expensive and not suitable for point of care
Solution Approach 1:
The patent employs a disposable lateral flow test strip that uses simple antibody-antigen binding chemistry instead of complex PCR machinery. The test strip is inexpensive, single-use, and can be performed at point of care, maintaining detection sensitivity while dramatically reducing device complexity and cost.
3Measurement precision
If serological tests are used, then sensitivity is improved, but they cannot detect early disease because patient antibodies are required
Solution Approach 1:
Instead of detecting patient antibodies against B. pertussis (serological approach), the patent inverts the approach by detecting B. pertussis antigens directly in the patient sample using labeled antibodies. This allows early detection before the patient's immune system produces detectable antibody levels, resolving the contradiction between sensitivity and detection timing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables immediate point-of-care diagnosis and treatment of pertussis, reducing disease severity, duration, and transmission by allowing for early antibiotic intervention and outbreak containment.
Implementation Method 1
anti-TcfA antibodies and fragments thereof are provided. In a particular embodiment, the anti-TcfA antibody or fragment thereof specifically binds amino acids 140-160, amino acids 229-240, amino acids 288-304, amino acids 286-321, amino acids 289-324, amino acids 305-323, amino acids 322-330, or amino acids 337-345 of TcfA
Data Source
AI summary
Compositions and methods for the detection of Bordetella pertussis and diagnosing pertussis are disclosed.